Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Vizz

(Aceclidine)

Small molecule

LLENZ Therapeutics, Inc

This eye drop medication is used to treat presbyopia, which is the age-related difficulty in focusing on close objects. It works by activating the eye muscle responsible for adjusting focus, helping to improve your ability to see nearby objects clearly.[1]

0

Indications

8

Total Trials

0

Active Trials

0

Competitors

1

FDA Application

NDA/BLA/ANDA regulatory filings

7

Patents

Clinical

Trials by Indication[1]

Presbyopia8 trials

Plasma Pharmacokinetics and Safety of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Subjects With Presbyopia

Completed·LLENZ Therapeutics, Inc·Phase 1·NCT05936489·30 enrolled

Phase 3 Safety Study for the Treatment of Presbyopia Subjects

Completed·LLENZ Therapeutics, Inc·Phase 3·NCT05753189·362 enrolled

A Single-Center, Double-Masked Evaluation of the Efficacy and Safety of PRX-100 in the Treatment of Early to Moderate Presbyopia

Completed·LLENZ Therapeutics, Inc·Phase 2·NCT03201562·58 enrolled

Show 5 more trials

Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Presbyopia

Completed·CCorxel Pharmaceuticals·Phase 3·NCT06045299·300 enrolled

Phase 3 Evaluation of the Safety and Efficacy of LNZ100 & LNZ101 for the Treatment of Presbyopia

Completed·LLENZ Therapeutics, Inc·Phase 3·NCT05656027·469 enrolled

Evaluation of the Safety and Effectiveness of Aceclidine/Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia

Completed·LLENZ Therapeutics, Inc·Phase 2·NCT05294328·68 enrolled

Phase 3 Efficacy Study of LNZ100 & LNZ101 for the Treatment of Presbyopia

Completed·LLENZ Therapeutics, Inc·Phase 3·NCT05728944·229 enrolled

Evaluation of the Safety and Effectiveness of Aceclidine (LNZ101) and Aceclidine + Brimonidine (LNZ100) in the Treatment of Presbyopia

Completed·LLENZ Therapeutics, Inc·Phase 2·NCT05431543·59 enrolled

Regulatory

FDA Approval Timeline[3]

Jul 31, 2025

VIZZ

NDA NDA218585

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Aceclidine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Aceclidine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
OpenFDA — FDA approval records (NDA NDA218585). U.S. Food & Drug Administration.
[4]
FDA Orange Book — Patent and exclusivity data for Vizz. U.S. Food & Drug Administration.
[5]
SEC EDGAR — LENZ Therapeutics, Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: LLENZ Therapeutics, Inc

Patent Landscape[4]

Patent Cliff

Mar 24, 2034

Earliest patent expiration — generic entry possible after this date

Patent #Expires

11179328Mar 24, 2034

9844537Mar 24, 2034

10052313Mar 24, 2034

12653779Jun 17, 2035

12128036Oct 8, 2039

2 more patents

12533347Oct 8, 2039

12414942Mar 15, 2044

Related News